IQVIA Releases Report on Utilization of Key Health Services as States Reopen
The IQVIA Institute for Human Data Science has released a new report which features a Reopening Readiness Index (RPI). It presents five criteria for easing restrictions in the United States and generates an aggregate readiness score based on progress in each category. The result is a consistent way to assess current readiness and to track progress – or regression – over time.
Thirteen states reach an aggregate score of 90 or more against an index level of 100 points; New York, Rhode Island, and New Jersey are the only states to meet or exceed that score, due in large part to high levels of testing and low current reproduction rates.
To compliment the RPI, IQVIA has also released a Health Services Utilization Index (HSUI), which measures the utilization of five key health services - including doctor visits, elective procedures and new prescriptions – as a signal of revival for the health system.
The HSUI shows must states are utilizing these key health services half as much as they did prior to COVID-19. This suggests that many patients are still facing delayed or deferred medical treatments. The revival of the health system is critical to ensuring all Americans receive treatments and/or prescriptions they need.
For the detailed IQVIA Reopening Readiness Index, click here.
Reshema Kemps-Polanco: Taking Risks for Greater Reward
May 14th 2025Reshema Kemps-Polanco, executive VP and chief commercial officer, Novartis US, and the 2025 Healthcare Businesswomen’s Association Woman of the Year, uses the lessons she learned from her family to bring out the best in her teams.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders
May 14th 2025Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.
